Advertisement
UK markets close in 6 hours 47 minutes
  • FTSE 100

    8,107.72
    +28.86 (+0.36%)
     
  • FTSE 250

    19,796.49
    +194.51 (+0.99%)
     
  • AIM

    755.81
    +2.69 (+0.36%)
     
  • GBP/EUR

    1.1663
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.2541
    +0.0030 (+0.24%)
     
  • Bitcoin GBP

    51,356.68
    +439.49 (+0.86%)
     
  • CMC Crypto 200

    1,388.99
    -7.54 (-0.54%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    83.79
    +0.22 (+0.26%)
     
  • GOLD FUTURES

    2,359.70
    +17.20 (+0.73%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,044.19
    +126.91 (+0.71%)
     
  • CAC 40

    8,039.80
    +23.15 (+0.29%)
     

Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal

AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. The deal could be worth up to nearly $1.8 billion including milestone payments. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss why AbbVie is teaming up with Regenxbio.